- Home
- TCRX
as 10-31-2025 10:00am EST
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 140.7M | IPO Year: | 2021 |
| Target Price: | $9.40 | AVG Volume (30 days): | 656.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $6.22 | Next Earning Date: | 11-07-2025 |
| Revenue: | $6,961,000 | Revenue Growth: | -42.94% |
| Revenue Growth (this year): | 255.18% | Revenue Growth (next year): | -14.14% |
Latest TScan Therapeutics Inc. News
TCRX Breaking Stock News: Dive into TCRX Ticker-Specific Updates for Smart Investing
Barchart
15 days ago
2 Overlooked Stocks to Snap Up in 2025
Barchart
4 months ago
2 Small-Cap Stocks Under $10 to Buy With Big Potential
GlobeNewswire
5 months ago
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
Zacks
6 months ago
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
6 months ago
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
6 months ago
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire
7 months ago
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
7 months ago
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Compare TCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.